MDMA: FDA ablates Zulassung von Ecstasy as a drug

MDMA is dangerous? US-Behörde lehnt Zulassung von Ecstasy als Medikament ab

The general treatment has no influence on the psychedelic treatment of posttraumatic traumatic experiences. Forscher criticizes that.

Christian Weber

Published today at 5:19 PM

Safely Used Ecstasy: Party Drug – or Other Experimental Drugs for Spiritual Guidance?

Photo: John Thys (AFP)

You can subscribe and make a profit from the previous function.

BotTalk

This single stage journey became an international event in its own right Victory of psychedelic drugs, The US government and the US Food and Drug Administration (FDA) have banned the company Lykos Therapeutics, one of its MDMA-based drugs used to treat post-traumatic stress disorder (PTBS).

The separation comes as the US traditionally commits its psychedelic medicine transgression as one of many European states. So the FDA says ketamine is relatively effective as an antidepressant. This is MDMA – marketed as Ecstasy – since 2023 in Australisch zur Behandlung von posttraumatischen Belastungsstörungen zuglassen. Study of the most likely effects. (Read an interview with a US Forscher: «Drying could clean the world».)

With psychedelics there is a problem with a placebo

Separating the psychedelics is a psychedelic psychedelic in medical therapy: it is a good idea to study the control groups in the study in an overloaded place. It may be that these substances, such as MDMA, Psilocybin, LSD or Ketamin, have a German psychedelic effect on the mind of the patient.

When adjusting dosages in the medical world, it is worth performing pseudo-hallucinations: the patients are sick, but it is not the case that they can use a drug. If this psychedelic effect does not work, it is a vermutliche placebo that does not work and is part of the control group. “Blinded studies are also volatile over time”, says Matthias Liechti, Chief Physician of Clinical Pharmacology and Toxicology at the University of Basel, the German Science Media Center.

Only: “An unpleasant blindness occurs in various studies”, says Pharmacology. Here the critical positioning was discussed. Under the problem of these problems Problem: So the man for the sake of example changes Dosage of the substance set and observe, what has an effect. There was a German hint on a specific way of working.

Other Forscher studies are based on the study results of study groups that make such a drying possible. Those people can exert a psychedelic effect with an active placebo. A Schwäche bisheriger study is not planning, if its patients with substanzerfahrung a teilnahme bemühen, who will recognize it, were they schlucken.

Who is MDMA for the Herz?

Streiten is no longer interested in the more relevant criticism, which was carried out by the FDA: Nebenwirkungen and the like of MDMA. The MDMA load is taxed by the Kreislauf and the reweighted patients at a certain point. Here you see more studies, said Matthias Liechti. This warning comes from the psychiatrist Gregor Hasler of the Schweizer Universität Freiburg.

“Building of the illegal expansion of MDMA” is a fact, while the substance is “for the heart”, is the Science Media Center. “In general, there are still some aspects to be clarified”, Liechti summarizes. “If you want to know what did not happen, you are not able to.”

We look behind one of the advantages of a psychedelic therapy to the treatment: if there is no comparison with classical psychopharmaceuticals, the very long time will be described. It is one of the most important forms of psychotherapy. “The FDA has reviewed the classification of this therapy as a drug treatment and required standards, which are unique in psychotherapy, but also in pharmaceutical therapy, which Hasler criticizes.

MDMA-Forschung in der Schweiz laäuft weiter

Insofern show auch die Warnungen for einem Missbrauch womöglich übertrieben: “That Such gefahr ist for me brighter as of the potenzielle Nutzen,” says Liechti. The patient does not have the MDMA pack at home on his nightly lie.

Researchers and researchers in the US and Europe are now working to separate the FDA from the psychedelic institution in the US market for the industry “from a greater understanding,” says Hasler. Research has been slow in Switzerland, Canada and Australia and producing failing data, Liechti explains. Now that this may be the case in Europe, it is urgent to use medicine and take care of the medication.

It is possible that the three research projects will be investigated by the journal “Psychopharmacology” that will be sent to the FDA. Let the journal not offend its ethical misunderstandings and the submitted data will not be removed from the analysis. Make sure the car is no longer interested. Research: The treatment with MDMA study by Lykos Therapeutics, which is being conducted by the FDA, played a role.

Found an error? Report it now.

Related Posts

Schwacher Handel in Frankfurt: MDAX fällt letztendlich zurück | 12.08.24

Ich flight über 100 Mal im Jahr: Diese Airline does not book any more

Kolibakerieen: Fast-Food-Ketten nehmen Zwiebeln vom Menü